Danielle Zachary
Clinical Nurse Specialist · Oklahoma City, OKNPI 1316171655
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 34.8% of the total.
Across 123 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$696
- Lilly USA, LLC$149
- Novo Nordisk$133
- Pfizer$114
- GSK$83
- Abbott$79
- plus $750 from 29 others
What the payments were for
- Food & beverage$2,003100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $696 |
| Lilly USA, LLC | 10 | $149 |
| Novo Nordisk | 8 | $133 |
| Pfizer | 8 | $114 |
| GSK | 6 | $83 |
| Abbott | 4 | $79 |
| AstraZeneca | 5 | $72 |
| Teva Pharmaceuticals USA, Inc. | 4 | $71 |
| Organon | 5 | $61 |
| Antares Pharma, Inc. | 2 | $44 |
| Corcept Therapeutics | 2 | $37 |
| Genentech USA, Inc. | 2 | $36 |
| Mannkind Corporation | 2 | $35 |
| Boehringer Ingelheim | 2 | $29 |
| Merck | 2 | $28 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Bayer | 1 | $17 |
| Nalu Medical, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Amgen | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Eisai Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$2,003 in reported general payments places this provider in the 65th percentile of 56 clinical nurse specialist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 83 | $99,498 |
| OzempicSemaglutide | 37 | $54,523 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $38,969 |
| XareltoRivaroxaban | 17 | $25,501 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 21 | $22,905 |
| TrulicityDulaglutide | 19 | $20,467 |
| JardianceEmpagliflozin | 13 | $20,113 |
| TradjentaLinagliptin | 14 | $18,779 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 13 | $16,588 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $16,477 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $13,250 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $9,948 |
| Repatha SureclickEvolocumab | 14 | $7,475 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $7,038 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $149 | $119,966102 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta | $29 | $61,79748 claims |
| Novo NordiskOzempic | $133 | $54,52337 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $83 | $20,77426 claims |
| MerckJanumet Xr, Januvia | $28 | $10,74725 claims |
| AbbVieSynthroid | $696 | $1,51818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 56 clinical nurse specialist providers in Oklahoma.
Other clinical nurse specialist in Oklahoma City
- Erica MelickOklahoma City$5K
- Kelly Lang-SheppardOklahoma City$5K
- Cheryl WestOklahoma City$4K
- April MerrillOklahoma City$2K
- Heather GrahamOklahoma City$2K
- Amy EberleOklahoma City$1K
- Robin MartinOklahoma City$1K
- Michelle PopeOklahoma City$1K
- Linda PitchfordOklahoma City$929
- Tara SukutOklahoma City$852
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.